$11.60
-0.11[-0.94%]
At close: Apr 25
$11.60
0[0.00%]
After Hours: 6:24PM EDT
Iovance Biotherapeutics
(NASDAQ:IOVA)Iovance Biotherapeutics Stock (NASDAQ:IOVA), Analyst Ratings, Price Targets, Predictions
Iovance Biotherapeutics Inc has a consensus price target of $20.82, established from looking at the 80 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, Truist Securities, and HC Wainwright & Co. on March 14, 2024, March 7, 2024, and March 4, 2024. With an average price target of $25.67 between Piper Sandler, Truist Securities, and HC Wainwright & Co., there's an implied 121.26% upside for Iovance Biotherapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Truist Securities
HC Wainwright & Co.
Wells Fargo
Goldman Sachs
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Iovance Biotherapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/14/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.60 | 63.79% | Piper Sandler | Joseph Catanzaro | $18 → $19 | Maintains | Overweight | Get Alert |
| 03/07/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.60 | 124.14% | Truist Securities | Asthika Goonewardene | $17 → $26 | Maintains | Buy | Get Alert |
| 03/04/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.60 | 175.86% | HC Wainwright & Co. | Joseph Pantginis | → $32 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.60 | 115.52% | Wells Fargo | Yanan Zhu | $22 → $25 | Maintains | Overweight | Get Alert |
| 02/29/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.60 | 175.86% | HC Wainwright & Co. | Joseph Pantginis | → $32 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.60 | 81.03% | Goldman Sachs | Andrea Tan | $19 → $21 | Maintains | Buy | Get Alert |
| 02/29/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.60 | 89.66% | Barclays | Peter Lawson | $18 → $22 | Maintains | Overweight | Get Alert |
| 02/21/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.60 | 63.79% | Goldman Sachs | Andrea Tan | $13 → $19 | Maintains | Buy | Get Alert |
| 02/20/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.60 | 115.52% | JMP Securities | Reni Benjamin | $18 → $25 | Maintains | Market Outperform | Get Alert |
| 02/20/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.60 | 89.66% | Wells Fargo | Yanan Zhu | $17 → $22 | Maintains | Overweight | Get Alert |
| 02/20/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.60 | 63.79% | Goldman Sachs | Andrea Tan | $13 → $19 | Maintains | Buy | Get Alert |
| 02/20/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.60 | 55.17% | Piper Sandler | Joseph Catanzaro | $14 → $18 | Maintains | Overweight | Get Alert |
| 02/20/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.60 | 193.1% | Chardan Capital | Geulah Livshits | $29 → $34 | Maintains | Buy | Get Alert |
| 12/27/2023 | IOVA | Buy Now | Iovance Biotherapeutics | $11.60 | 141.38% | HC Wainwright & Co. | Joseph Pantginis | $38 → $28 | Maintains | Buy | Get Alert |
| 12/27/2023 | IOVA | Buy Now | Iovance Biotherapeutics | $11.60 | 46.55% | Truist Securities | Asthika Goonewardene | $17 → $17 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2023 | IOVA | Buy Now | Iovance Biotherapeutics | $11.60 | 3.45% | Goldman Sachs | Andrea Tan | → $12 | Initiates | → Buy | Get Alert |
| 11/08/2023 | IOVA | Buy Now | Iovance Biotherapeutics | $11.60 | 141.38% | HC Wainwright & Co. | Joseph Pantginis | $38 → $28 | Maintains | Buy | Get Alert |
| 09/18/2023 | IOVA | Buy Now | Iovance Biotherapeutics | $11.60 | 55.17% | Barclays | Peter Lawson | $40 → $18 | Maintains | Overweight | Get Alert |
| 09/15/2023 | IOVA | Buy Now | Iovance Biotherapeutics | $11.60 | 46.55% | Truist Securities | Asthika Goonewardene | → $17 | Reiterates | Buy → Buy | Get Alert |
FAQ
What is the target price for Iovance Biotherapeutics (IOVA)?
The latest price target for Iovance Biotherapeutics (NASDAQ: IOVA) was reported by Piper Sandler on March 14, 2024. The analyst firm set a price target for $19.00 expecting IOVA to rise to within 12 months (a possible 63.79% upside). 44 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Iovance Biotherapeutics (IOVA)?
The latest analyst rating for Iovance Biotherapeutics (NASDAQ: IOVA) was provided by Piper Sandler, and Iovance Biotherapeutics maintained their overweight rating.
When was the last upgrade for Iovance Biotherapeutics (IOVA)?
The last upgrade for Iovance Biotherapeutics Inc happened on May 30, 2023 when Wells Fargo raised their price target to $17. Wells Fargo previously had an equal-weight for Iovance Biotherapeutics Inc.
When was the last downgrade for Iovance Biotherapeutics (IOVA)?
The last downgrade for Iovance Biotherapeutics Inc happened on December 9, 2022 when Goldman Sachs changed their price target from $20 to $6 for Iovance Biotherapeutics Inc.
When is the next analyst rating going to be posted or updated for Iovance Biotherapeutics (IOVA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Iovance Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Iovance Biotherapeutics was filed on March 14, 2024 so you should expect the next rating to be made available sometime around March 14, 2025.
Is the Analyst Rating Iovance Biotherapeutics (IOVA) correct?
While ratings are subjective and will change, the latest Iovance Biotherapeutics (IOVA) rating was a maintained with a price target of $18.00 to $19.00. The current price Iovance Biotherapeutics (IOVA) is trading at is $11.60, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.